Who are Metronidazole Vaginal's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Metronidazole Topical Gel 2%, Metronidazole Suppositories, Metronidazole gel 1%, Fexinidazole, Solosec, BISMUTH SUBCITRATE POTASSIUM.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/metronidazole-vaginal.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Metronidazole Vaginal — Competitive Intelligence Brief

Metronidazole Vaginal (Metronidazole Vaginal) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nitroimidazole antimicrobial. Area: Infectious Disease.

marketed Nitroimidazole antimicrobial Bacterial/protozoal DNA Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Metronidazole Vaginal (Metronidazole Vaginal) — Peking University Shenzhen Hospital. Metronidazole is a nitroimidazole antimicrobial that disrupts bacterial and protozoal DNA, leading to cell death.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Metronidazole Vaginal TARGET	Metronidazole Vaginal	Peking University Shenzhen Hospital	marketed	Nitroimidazole antimicrobial	Bacterial/protozoal DNA
Metronidazole Topical Gel 2%	Metronidazole Topical Gel 2%	Jinnah Postgraduate Medical Centre	marketed	Nitroimidazole antimicrobial	Bacterial/protozoal DNA
Metronidazole Suppositories	Metronidazole Suppositories	Dongfang Hospital Beijing University of Chinese Medicine	marketed	Nitroimidazole antibiotic	Bacterial/protozoal DNA
Metronidazole gel 1%	Metronidazole gel 1%	Galderma R&D	marketed	Nitroimidazole antimicrobial	Bacterial/protozoal DNA
Fexinidazole	FEXINIDAZOLE	Sanofi	marketed	Nitroimidazole Antimicrobial [EPC]		2021-01-01
Solosec	SECNIDAZOLE	Evofem Inc	marketed	Nitroimidazole Antimicrobial [EPC]		2017-01-01
BISMUTH SUBCITRATE POTASSIUM	BISMUTH SUBCITRATE POTASSIUM		marketed	Nitroimidazole Antimicrobial [EPC]		2006-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nitroimidazole antimicrobial class)

Galderma R&D · 2 drugs in this class
University of Guarulhos · 2 drugs in this class
Jinnah Postgraduate Medical Centre · 1 drug in this class
Peking University Shenzhen Hospital · 1 drug in this class
University of Toronto · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Metronidazole Vaginal — Competitive Intelligence Brief. https://druglandscape.com/ci/metronidazole-vaginal. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab